Anamar AB
Records under this name other than the patents Anamar AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,632,097 | Determining Pathological Cartilage Turnover Formerly held In force · High confidence | In force | High confidence | |
| US 8,410,174 | Method for treating arthritis Formerly held Lapsed on the fee record Ended Apr 2, 2021 · From the USPTO record | Lapsed on the fee record | Ended Apr 2, 2021 | From the USPTO record |
| US 8,372,878 | Aminoguanidines as melanocortin receptor ligands Formerly held Lapsed on the fee record Ended Feb 12, 2021 · From the USPTO record | Lapsed on the fee record | Ended Feb 12, 2021 | From the USPTO record |
| US 8,110,663 | Monoclonal antibodies for cartillage oligomeric matrix protein Term ended Term ended Nov 22, 2020 · From the USPTO record | Term ended | Term ended Nov 22, 2020 | From the USPTO record |
| US 8,309,609 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands Formerly held Lapsed on the fee record Ended Nov 13, 2020 · From the USPTO record | Lapsed on the fee record | Ended Nov 13, 2020 | From the USPTO record |
| US 8,227,502 | Amides acting on the adenosine receptors Formerly held Lapsed on the fee record Ended Jul 24, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jul 24, 2020 | From the USPTO record |
| US 8,148,429 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands Formerly held Lapsed on the fee record Ended Apr 3, 2020 · From the USPTO record | Lapsed on the fee record | Ended Apr 3, 2020 | From the USPTO record |
| US 9,227,927 | Method of treating inflammation Formerly held Lapsed on the fee record Ended Jan 5, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jan 5, 2020 | From the USPTO record |
| US 7,956,047 | Use of chondroitin sulphate E (CS-E) for the treatment of diseases or conditions related to collagen fibril formation Formerly held Lapsed on the fee record Ended Jun 7, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jun 7, 2019 | From the USPTO record |
| US 7,153,881 | Compounds acting as melanocortin receptor ligands Formerly held Lapsed on the fee record Ended Dec 26, 2018 · From the USPTO record | Lapsed on the fee record | Ended Dec 26, 2018 | From the USPTO record |